Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
SueWallSt announced an investigation into Abivax regarding potential securities law violations tied to disclosures about rare malignancy cases in its Phase 3 ABTECT trial. The firm is soliciting investors who experienced losses during the recent 40%+ stock decline to contact them for a free case evaluation.
Key figures
- Short interest
- 12%
- Midday low price
- $71
- Prior close price
- $129.69
- Stock drop percentage
- more than 40%
- Jefferies price target cut to
- $90
- Jefferies price target cut from
- $160
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.